These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1421415

  • 1. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation.
    Yeager AM, Wagner JE, Graham ML, Jones RJ, Santos GW, Grochow LB.
    Blood; 1992 Nov 01; 80(9):2425-8. PubMed ID: 1421415
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A, Wong E, Nath C, Janson B, Harrison SJ, Hoyt R, Bajel A, Shaw P, Ritchie D, Grigg A.
    Ann Hematol; 2018 Dec 01; 97(12):2509-2518. PubMed ID: 30051172
    [Abstract] [Full Text] [Related]

  • 3. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS.
    Biol Blood Marrow Transplant; 2002 Dec 01; 8(9):468-76. PubMed ID: 12374451
    [Abstract] [Full Text] [Related]

  • 4. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
    Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP, Garbriel D, Serody J, Kirby S, Wiley J.
    Anticancer Drugs; 2004 Jun 01; 15(5):453-9. PubMed ID: 15166618
    [Abstract] [Full Text] [Related]

  • 5. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ, Nath C, Berry A, Earl JW.
    Bone Marrow Transplant; 2004 Aug 01; 34(3):197-205. PubMed ID: 15195074
    [Abstract] [Full Text] [Related]

  • 6. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.
    Biol Blood Marrow Transplant; 2004 Sep 01; 10(9):614-23. PubMed ID: 15319773
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY.
    Bone Marrow Transplant; 2011 Jan 01; 46(1):27-33. PubMed ID: 20305698
    [Abstract] [Full Text] [Related]

  • 8. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb R, Slattery JT.
    Bone Marrow Transplant; 1996 Mar 01; 17(3):341-6. PubMed ID: 8704684
    [Abstract] [Full Text] [Related]

  • 9. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
    Gaziev J, Isgrò A, Mozzi AF, Petain A, Nguyen L, Ialongo C, Dinallo V, Sodani P, Marziali M, Andreani M, Testi M, Paciaroni K, Gallucci C, De Angelis G, Alfieri C, Ribersani M, Lucarelli G.
    Pediatr Blood Cancer; 2015 Apr 01; 62(4):680-6. PubMed ID: 25557687
    [Abstract] [Full Text] [Related]

  • 10. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
    Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O.
    Cancer Chemother Pharmacol; 1996 Apr 01; 37(3):247-53. PubMed ID: 8529285
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep 01; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 13. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K, Valerie B, Claire G, Valerie M, Yves B, Gilles A, Nathalie B.
    Pharmacoepidemiol Drug Saf; 2008 Feb 01; 17(2):135-43. PubMed ID: 17952879
    [Abstract] [Full Text] [Related]

  • 14. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H, Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.
    Ther Drug Monit; 2014 Feb 01; 36(1):93-9. PubMed ID: 24061446
    [Abstract] [Full Text] [Related]

  • 15. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
    Clopés A, Sureda A, Sierra J, Queraltó JM, Broto A, Farré R, Moreno E, Brunet S, Martino R, Mangues MA.
    Eur J Haematol; 2006 Jul 01; 77(1):1-6. PubMed ID: 16573745
    [Abstract] [Full Text] [Related]

  • 16. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
    Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE.
    Biol Blood Marrow Transplant; 2002 Jul 01; 8(9):477-85. PubMed ID: 12374452
    [Abstract] [Full Text] [Related]

  • 17. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.
    Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M.
    Blood; 1993 Apr 15; 81(8):2194-9. PubMed ID: 8471779
    [Abstract] [Full Text] [Related]

  • 18. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
    Grochow LB.
    Semin Oncol; 1993 Aug 15; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
    Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS.
    Biol Blood Marrow Transplant; 2002 Aug 15; 8(9):486-92. PubMed ID: 12374453
    [Abstract] [Full Text] [Related]

  • 20. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
    Chattergoon DS, Saunders EF, Klein J, Calderwood S, Doyle J, Freedman MH, Koren G.
    Bone Marrow Transplant; 1997 Sep 15; 20(5):347-54. PubMed ID: 9339748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.